The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011TFEB and Its Associated MicroRNA-128 as Targets for Neuroprotection and Disease Intervention in Parkinson´s Disease
Objective/Rationale:
Recent studies indicate that degenerative changes seen in Parkinson´s disease (PD) may be linked to impairments in the cells´ ability to degrade toxic proteins, such as misfolded... -
Therapeutics Development Initiative, 2011Novel Oral Treatment for Parkinson's Disease Based on Highly Specific Modulation of the Indirect Pathway
Objective/Rationale:
Envoy Therapeutics’ target discovery technology enables the identification of new drug targets that have very selective expression in brain circuits of therapeutic interest thereby... -
Alpha-Synuclein Imaging, 2011Consortium to Develop an Alpha-synuclein Imaging Agent
Objective/Rationale:
The ultimate goal of this project is develop a positron emission tomography (PET) radiotracer to image the distribution of alpha-synuclein in the brain. Alpha-synuclein imaging... -
Research Grant, 2011Testing Effects of Improved Levodopa Delivery with Dexterity and Gait Objective Measures
Objective/Rationale:
The objective of this project is to develop an extended-release capsule of levodopa/carbidopa (IPX066) that will result in constant blood levels of levodopa compared to current... -
Repositioning Drugs for PD, 2011Duloxetine Hydrochloride as a Novel Neuroprotective Treatment for Parkinson's Disease
Objective/Rationale:
In Parkinson’s disease (PD) dopaminergic neurons in the midbrain region substantia nigra pars compacta die. There is currently no treatment available that prevents this cell death... -
Repositioning Drugs for PD, 2011Evaluation of a Specific DAT Inhibitor in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
MLR-1017 is a psychostimulant drug used clinically for a variety of neuropsychiatric and other applications, but has never been tested in Parkinson’s disease (PD). Levodopa is a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.